Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells

Journal of Cellular Physiology

Volumn 205, Issue 2, 2005, Pages 218-227

  Johnson, Faye M ^a   Saigal, Babita ^a   Donato, Nicholas J ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NEUTRALIZING ANTIBODY; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CELL GROWTH; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SECRETION; RECEPTOR UPREGULATION; SARCOMA; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STEM CELL FACTOR;

EID: 26444530067     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20383     Document Type: Article

References (48)

1. Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, Andre T, Mareel M, Mester J, Gespach C. 2002. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62 (17):4879-4883.
2. Barnes DW. 1982. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J Cell Biol 93(1);1-4.
3. Baskaynak G, Kreuzer KA, Schwarz M, Zuber J, Audring H, Riess H, Dorken B, le Coutre P. 2003. Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Haematol 70(4):231-234.
4. Benhar M, Engelberg D, Levitzki A. 2002. Cisplatin-induced activation of the EGF receptor. Oncogene 21(57):8723-8731.
5. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB. 1996. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56(1):100-104.
6. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139-145.
7. Chu S, Holtz M, Gupta M, Bhatia R. 2004. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103(8):3167-3174.
8. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. 2003. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101(12):4714-4716.
9. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561-566.
10. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. 2001a. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14):1038-1042.
11. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. 2001b. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031-1037.
12. Ebnoether M, Stentoft J, Ford J, Buhl L, Gratwohl A. 2002. Cerebral oedema as a possible complication of treatment with imatinib. Lancet 359(9319):1751-1752.
13. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH. 2001. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7- ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 61(2):739-748.
14. Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, Talpaz M. 2002. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95 (4):881-887.
15. Fan Z, Shang BY, Lu Y, Chou JL, Mendelsohn J. 1997. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 3(11):1943-1948.
16. Fang L, Li G, Liu G, Lee SW, Aaronson SA. 2001. p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J 2(8):1931-1939.
17. Frank DK, Frederick MJ, Liu TJ, Clayman GL. 1998. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin Cancer Res 4(10):2521-2528.
18. Frasca F, Vigneri P, Vella V, Vigneri R, Wang JY. 2001. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor. Oncogene 20(29):3845-3856.
19. Gleich LL, Srivastava L, Gluckman JL. 1996. Plasma platelet-derived growth factor: Preliminary study of a potential marker in head and neck cancer. Ann Otol Rhinol Laryngol 105(9):710-712.
20. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. 2000. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 96(3):925-932.
21. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P. 2004. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64(7):2333-2337.
22. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, Wang WS, Yen CC, Chen PM. 2002. Stevens-Johnson syndrome after treatment with STI571: A case report. Br J Haematol 117(3):620-622.
23. Iwamoto R, Mekada E. 2000. Heparin-binding EGF-like growth factor: A juxtacrine growth factor. Cytokine Growth Factor Rev 11(4):335-344.
24. Iwamoto R, Handa K, Mekada E. 1999. Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor. J Biol Chem 274(36):25906-25912.
25. Konstantopoulos K, Papadogianni A, Dimopoulou M, Kourelis C, Meletis J. 2002. Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology 205 (2):172-173.
26. Krystal GW, Honsawek S, Litz J, Buchdunger E. 2000. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6(8):3319-3326.
27. Kwok TT, Sutherland RM. 1991. Epidermal growth factor reduces resistance to doxorubicin. Int J Cancer 49(1):73-76.
28. Laderoute KR, Ausserer WA, Knapp AM, Grant TD, Sutherland RM. 1994. Epidermal growth factor modifies cell cycle control in A431 human squamous carcinoma cells damaged by ionizing radiation. Cancer Res 54(6):1407-1411.
29. Lansford CD, Grenman R, Bier H, Somers KD, Kim SY, Whiteside TL, Clayman GL, Welkoborsky HI, Carey TE. 1999. Head and Neck Cancers. In: Palsson B, Masters JRW, editors. Cancer cell lines. Norwell, MA: Kluwer Academic Publishers. p 185-255.
30. Liu TJ, el-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, CLayman GL. 1995. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55(14):3117-3122.
31. Lu Z, Ghosh S, Wang Z, Hunter T. 2003. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4(6):499-515.
32. MacLeod CL, Luk A, Castagnola J, Cronin M, Mendelsohn J. 1986. EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells. J Cell Physiol 127 (1):175-182.
33. Mino M, Pilch BZ, Faquin WC. 2003. Expression of KIT (CD117) in neoplasms of the head and neck: An ancillary marker for adenoid cystic carcinoma. Mod Pathol 16(12):1224-1231.
34. Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M, Mekada E. 1995. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 270(3):1015-1019.
35. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. 1996. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12 (8):1617-1623.
36. Ocharoenrat P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, Eccles SA. 2000. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 60(4):1121-1128.
37. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. 2002. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8(3):289-293.
38. Park NH, Min BM, Li SL, Huang MZ, Cherick HM, Doniger J. 1991. Immortalization of normal human oral keratinocytes with type 16 human papillomavirus. Carcinogenesis 12(9):1627-1631.
39. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R. 2004. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22(5):935-942.
40. Prime SS, Game SM, Matthews JB, Stone A, Donnelly MJ, Yeudall WA, Patel V, Sposto R, Silverthorne A, Scully C. 1994. Epidermal growth factor and transforming growth factor alpha characteristics of human oral carcinoma cell lines. Br J Cancer 69(1):8-15.
41. Schreiber E, Matthias P, Muller MM, Schaffner W. 1989. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17(15):6419.
42. Schwarz M, Kreuzer KA, Baskaynak G, Dorken B, le Coutre P. 2002. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 69(4):254-256.
43. Strawn LM, Kabbinavar F, Schwartz DP, Mann E, Shawver LK, Slamon DJ, Cherrington JM. 2000. Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. Clin Cancer Res 6(7):2931-2940.
44. Takenobu H, Yamazaki A, Hirata M, Umata T, Mekada E. 2003. The stress- and inflammatory cytokine-induced ectodomain shedding of heparin-binding epidermal growth factor-like growth factor is mediated by p38 MAPK, distinct from the 12-O-tetradecanoylphorbol-13-acetate- and lysophosphatidic acid-induced signaling cascades. J Biol Chem 278(19):17255-17262.
45. Thomas GR, Tubb EE, Sessions RB, Cullen KJ. 1993. Growth factor mRNA expression in human head and neck malignant tumors. Arch Otolaryngol Head Neck Surg 119(11):1247-1252.
46. Vidal D, Puig L, Sureda A, Alomar A. 2002. Sti571-induced Stevens-Johnson Syndrome. Br J Haematol 119(1):274-275.
47. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R. 2000. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571. Oncogene 19(31):3521-3528.
48. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S. 2002. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62(1):188-199.